Article
Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation.
Respiratory research - 11 May 2021
Li Changhui, Nie Wei, Guo Jingdong, Xiong Anning, Zhong Hua, Chu Tianqing, Zhong Runbo, Xu Jianlin, Lu Jun, Zheng Xiaoxuan, Zhang Bo, Shen Yinchen, Pan Feng, Han Baohui, Zhang Xueyan
Abstract excerpt
BACKGROUND: This study was designed to investigate the difference between brain metastases (BM) and non-brain metastases (non-BM) treated by osimertinib in advanced patients with an acquired EGFR T790M mutation after obtaining first-generation EGFR-TKI resistance. METHODS: A total number of 135 first-generation EGFR-TKI-resistant patients with an acquired EGFR T790M mutation were retrospectively analyzed. The...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.